Likewise, given that the presence of inflammation differentiates NASH from steatosis, further studies comparing serum levels of ASC, IL-18, and Gal-3 in patients with NASH to those with steatosis may help validate these potential biomarkers for NASH. This evidence concerns the gene LGALS3 and steatosis.